Inactive Instrument

MDxHealth SA Euronext Bruxelles

Equities

MDXH

BE0974461940

Biotechnology & Medical Research

MDxHealth SA Provides Revenue Guidance for the Year 2022 and Reaffirms Revenue Guidance for the Year 2023

January 09, 2023 at 04:00 pm EST

MDxHealth SA provided revenue guidance for the year 2022 and reaffirmed revenue guidance for the year 2023. For the year 2022, Company expects to report 2022 revenues of approximately $37 million.
For the year 2023, Company is also reaffirming its previously issued revenue guidance of $65 million -$70 million.

Latest news about MDxHealth SA

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering	Mar. 12	CI
Piper Sandler Adjusts Price Target on MDxHealth to $7 From $6, Maintains Overweight Rating	Mar. 07	MT
MDxHealth SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 06	CI
Transcript : MDxHealth SA, Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Earnings Flash (MDXH) MDXHEALTH Posts Q4 Revenue $19.4M	Mar. 06	MT
MDxHealth SA Maintains Earnings Guidance for the Year 2024	Mar. 06	CI
MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors	Feb. 16	CI
MDxHealth Preliminary Q4 Revenue Tops Consensus; 2024 Outlook Exceeds Estimates; Shares Jump After Hours	Jan. 08	MT
MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024	Jan. 08	CI

Chart MDxHealth SA

Duration

Period

More charts

Company Profile

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Companyâs tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research